REVEAL-Vasc
Research type
Research Study
Full title
A cross-sectional REVEAL sub-study evaluating the effect of anacetrapib on vascular function and arterial stiffness [An investigator led sub-study of HPS3/TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease]
IRAS ID
146810
Contact name
Joseph Cheriyan
Contact email
Duration of Study in the UK
2 years, 2 months, 1 days
Research summary
Cholesterol is transported through the bloodstream by two lipoproteins known as LDL-C and HDL-C. LDL-C can form hard deposits known as plaques which block the arteries, causing atherosclerosis. The plaques can restrict blood flow, or break-up and cause blood clots, which increases the risk of coronary events e.g. stroke and heart attack. Whilst drugs that decrease LDL-C reduce the risk of coronary events, there is still a residual cardiovascular risk. HDL-C helps remove LDL-C from the arteries; therefore increasing HDL-C levels may be effective for reducing residual cardiovascular risk. Anacetrapib is a drug being tested which increases HDL-C and research has shown that it can reduce atherosclerosis and increase the plaque stability.
Increased stiffness of the arteries is a predictor of cardiovascular outcomes, and can directly accelerate the development of plaques (atherogenesis). In addition, impaired function of the walls of blood vessels plays a key role in atherogenesis and it has been suggested that it can explain, at least in part, the residual cardiovascular risk in patients on aggressive LDL-C lowering treatment.
There are currently no studies evaluating the effect of anacetrapib on blood vessel function and stiffness of the arteries. The REVEAL-Vasc trial will assess whether anacetrapib, in addition to atorvastatin (LDL-C lowering drug) treatment, results in better functioning of the blood vessel walls and stiffness of the arteries.
Participants will be asked to provide a blood sample and pulse Wave Velocity/Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness of the arteries. REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (NCT01252953) which is coordinated by OXFORD CTSU. No treatment received on this sub-study, therefore only participants who have been enrolled in HPS3/TIMI55 REVEAL in which participants received anacetrapib with atorvastatin or placebo will be considered for this trial.REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
16/EM/0269
Date of REC Opinion
4 Aug 2016
REC opinion
Further Information Favourable Opinion